Drugs / Recombinant Human Adenovirus Type 5
Recombinant Human Adenovirus Type 5
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT07356791 | Feb → Dec 2026 expected | bladder transitional cell carcinoma | RenJi Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06618391 | Oct 2024 → Mar 2026 overdue | non-small cell lung carcinoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06253598 | Mar 2024 → Dec 2025 overdue | hepatocellular carcinoma | The First Affiliated Hospital of Bengbu Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05872841 | Jun 2023 → Dec 2024 | hepatocellular carcinoma, portal vein thrombosis | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01869088 | Jan 2013 → Jan 2018 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05124002 | Aug 2022 → Apr 2026 | intrahepatic cholangiocarcinoma | Beijing Tsinghua Chang Gung Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05113290 | Dec 2021 → Dec 2023 | hepatocellular carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Adenovirus Type 5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06253598 ↗ |
| Known as | H101 | “Effect and Safety of Recombinant Human Adenovirus Type 5 (H101) in Advanced Hepatocellular Carcinoma Patients With Stable Disease After Sorafenib Treatment: A Randomized,...” NCT05113290 ↗ |
| Known as | Recombinant Human Adenovirus Type 5 Injection | “Recombinant Human Adenovirus Type 5 Injection is an oncolytic adenovirus antitumor drug.” NCT07356791 ↗ |
| Route | Other | “will be first infused through the target artery” NCT01869088 ↗ |